Department of Respiratory Medicine, NHO Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo, 204-8585, Japan; Center for Pulmonary Circulation and Hemoptysis, Department of Respiratory Medicine, NHO Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo, 204-8585, Japan.
Department of Respiratory Medicine, NHO Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo, 204-8585, Japan; Center for Pulmonary Circulation and Hemoptysis, Department of Respiratory Medicine, NHO Tokyo National Hospital, 3-1-1 Takeoka, Kiyose, Tokyo, 204-8585, Japan.
Respir Investig. 2024 Nov;62(6):1034-1036. doi: 10.1016/j.resinv.2024.09.002. Epub 2024 Sep 7.
In 2022, the European Society of Cardiology (ESC) and the European Respiratory Society (ERS) proposed new diagnostic criteria for pulmonary hypertension (PH). These criteria include significant changes to the definitions of pulmonary hemodynamic indices. Specifically, the threshold for mean pulmonary artery pressure (mPAP) has been lowered from ≥25 mmHg to >20 mmHg, and the threshold for pulmonary vascular resistance (PVR) has been adjusted from ≥3 Wood units (WU) to >2 WU. Additionally, the diagnostic criterion for exercise-induced PH has been reintroduced. To differentiate between non-severe and severe PH associated with lung disease, a differential threshold of 5 WU for PVR has been proposed. However, the threshold for mean pulmonary artery wedge pressure (PAWP) remains unchanged. While these new criteria could provide a more refined approach to clinical practice, they may also raise clinical concerns and questions regarding the diagnosis and management of PH.
2022 年，欧洲心脏病学会（ESC）和欧洲呼吸学会（ERS）提出了肺动脉高压（PH）的新诊断标准。这些标准包括对肺血流动力学指数定义的重大改变。具体来说，平均肺动脉压（mPAP）的阈值已从≥25mmHg 降低到>20mmHg，而肺血管阻力（PVR）的阈值已从≥3 伍德单位（WU）调整为>2WU。此外，运动诱导性 PH 的诊断标准也被重新引入。为了区分与肺部疾病相关的非重度和重度 PH，建议将 PVR 的差异阈值设定为 5WU。然而，平均肺动脉楔压（PAWP）的阈值保持不变。虽然这些新标准可能为临床实践提供更精细的方法，但它们也可能引起临床关注和对 PH 的诊断和管理提出疑问。
